The FDA announced approval of cemiplimab-rwlc for basal cell carcinoma (BCC), giving dermatologists managing locally advanced and metastatic BCC now have another option in their toolbox.
A study in Laryngoscope investigated which pediatric melanoma anatomical site had the worst outcomes, finding that head and neck had a worse survival rate than any other body site.
The FDA announced approval of cemiplimab-rwlc for basal cell carcinoma (BCC), giving dermatologists managing locally advanced and metastatic BCC now have another option in their toolbox.
Pediatric melanoma in Hispanics presents at a younger age, has predominance in the lower limb, are Spitzoid melanomas, and are thicker tumors compared with non-Hispanic Whites, according to a recently